SAB Biotherapeutics, Inc. (SABS)
SABS Stock Price Chart
Explore SAB Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SABS price movements and trends.
SABS Company Profile
Discover essential business fundamentals and corporate details for SAB Biotherapeutics, Inc. (SABS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Feb 2021
Employees
86.00
Website
https://www.sab.bioCEO
Samuel J. Reich
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABS Financial Timeline
Browse a chronological timeline of SAB Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.29, while revenue estimate is $125.00k.
Earnings released on 12 May 2026
EPS came in at -$0.35 falling short of the estimated -$0.20 by -75.00%.
Earnings released on 9 Mar 2026
EPS came in at -$0.46 falling short of the estimated -$0.16 by -187.50%.
Earnings released on 14 Nov 2025
EPS came in at -$0.21 surpassing the estimated -$0.59 by +64.41%.
Earnings released on 7 Aug 2025
EPS came in at -$1.09 falling short of the estimated -$0.82 by -32.93%.
Earnings released on 9 May 2025
EPS came in at -$0.56 surpassing the estimated -$1.00 by +44.00%.
Earnings released on 28 Mar 2025
EPS came in at -$1.23 falling short of the estimated -$1.16 by -6.03%, while revenue for the quarter reached $100.00k , missing expectations by -16.67%.
Earnings released on 6 Nov 2024
EPS came in at -$1.12 falling short of the estimated -$1.07 by -4.67%, while revenue for the quarter reached -$410.00 , missing expectations by -100.27%.
Earnings released on 8 Aug 2024
EPS came in at -$0.79 surpassing the estimated -$1.13 by +30.09%, while revenue for the quarter reached $263.14k .
Earnings released on 20 May 2024
EPS came in at -$0.54 surpassing the estimated -$0.98 by +44.90%, while revenue for the quarter reached $944.58k .
Earnings released on 1 Apr 2024
EPS came in at -$3.38 falling short of the estimated -$0.62 by -445.16%, while revenue for the quarter reached $305.01k .
Stock split effective on 5 Jan 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $1.27m , beating expectations by +10.49k%.
Earnings released on 21 Aug 2023
EPS came in at -$1.40 surpassing the estimated -$1.60 by +12.50%, while revenue for the quarter reached $85.52k , missing expectations by -79.14%.
Earnings released on 16 May 2023
EPS came in at -$1.50 falling short of the estimated -$0.80 by -87.50%, while revenue for the quarter reached $600.00k , missing expectations by -76.38%.
Earnings released on 14 Apr 2023
EPS came in at -$1.56 falling short of the estimated -$0.04 by -3.81k%, while revenue for the quarter reached $2.16m , missing expectations by -66.75%.
Earnings released on 15 Nov 2022
EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%, while revenue for the quarter reached $3.59m , missing expectations by -39.18%.
Earnings released on 10 Aug 2022
EPS came in at -$1.10 surpassing the estimated -$1.30 by +15.38%, while revenue for the quarter reached $6.35m , missing expectations by -41.19%.
Earnings released on 12 May 2022
EPS came in at -$1.50 falling short of the estimated -$1.20 by -25.00%, while revenue for the quarter reached $11.80m , beating expectations by +2.93%.
Earnings released on 29 Mar 2022
EPS came in at -$0.66 falling short of the estimated -$0.11 by -500.00%, while revenue for the quarter reached $60.88m , meeting expectations.
Earnings released on 22 Nov 2021
EPS came in at -$0.02 surpassing the estimated -$0.09 by +77.78%, while revenue for the quarter reached $14.70m , missing expectations by -13.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.68 .
SABS Stock Performance
Access detailed SABS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
